ASX: IPD - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Badger Meter (BMI) adds UK sewer monitoring platform UDlive in $100m expansion move

Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?

What Alamar Biosciences’ (NASDAQ: ALMR) IPO pop says about the next phase of proteomics investing

UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control

Visual comparison of top ASX-listed medtech companies in 2025—Cardiex, ResMed, ImpediMed, and Volpara—highlighting their innovation focus, AI integration, and stock momentum.

Read More

Healthcare Industry News

How Cardiex, ResMed, ImpediMed, and Volpara are shaping Australia’s MedTech future in 2025

Comparing Cardiex, ResMed, ImpediMed, and Volpara in 2025 to see which ASX medtech firm is best positioned for growth in diagnostics, AI, and digital health.

byPallavi Madhiraju

June 2, 2025

web analytics